{
    "2020-10-27": [
        [
            {
                "time": "2023-10-25",
                "original_text": "Analyst Report: Novartis AG",
                "features": {
                    "keywords": [
                        "Novartis",
                        "AG",
                        "analyst report"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-25",
                "original_text": "Novartis Earnings Top, Sales Miss; NVS Stock Falls",
                "features": {
                    "keywords": [
                        "Novartis",
                        "earnings",
                        "sales miss",
                        "stock falls"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-25",
                "original_text": "Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Q3 earnings",
                        "surpass estimates",
                        "sales miss"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2023-10-25",
                "original_text": "Novartis: Q3 Earnings Insights",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Q3 earnings",
                        "insights"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-25",
                "original_text": "Novartis upbeat as drugmakers see hospitals coping with COVID",
                "features": {
                    "keywords": [
                        "Novartis",
                        "upbeat",
                        "drugmakers",
                        "hospitals",
                        "COVID"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-25",
                "original_text": "Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.",
                "features": {
                    "keywords": [
                        "Novartis",
                        "solid Q3 performance",
                        "core operating income growth",
                        "pipeline progression",
                        "guidance upgrade"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}